Appendix 1. Bibliography

Articles Accepted for Efficacy Analysis Revised

1. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. *Int J Obes Relat Metab Disord* 1992;16(4):269-77. Rec#: 7
   Notes: Considered for efficacy and adverse event analysis.

2. Astrup A, Breum L, Toubro S, Hein P, Quaade F. Ephedrine and weight loss. *Int J Obes Relat Metab Disord* 1992;16(9):715. Rec#: 8
   Notes: Not considered for analysis. Same trial as Astrup, 1992. Rec#7.

3. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. *Metabolism* 1992;41(7):686-8. Rec#: 9
   Notes: Considered for efficacy and adverse event analysis.

4. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. *Metabolism* 1991;40(3):323-9. Rec#: 13
   Notes: Considered for efficacy and adverse event analysis.

5. Belfie L, Petrie H, Chown S, et al. Safety and effectiveness of an herbal dietary supplement containing ephedra (ma huang) and caffeine (guarana extract) when used in combination with a supervised diet and exercise intervention. *Obesity Research Program Abstracts* 9(Suppl 3):26. Rec#: 317
   Notes: Considered for efficacy and adverse event analysis.

6. Bell DG, Jacobs I. Combined caffeine and ephedrine ingestion improves run times of Canadian Forces Warrior Test. *Aviat Space Environ Med* 1999;70(4):325-9. Rec#: 24
   Notes: Considered for efficacy and adverse event analysis.

7. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. *Med. Sci. Sports Exercise* 2001;33:1399-1403. Rec#: 512
   Notes: Considered for efficacy and adverse event analysis.

8. Bell DG, Jacobs I, McLellan TM, Miyazaki M, Sabiston CM. Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion. *Aviat Space Environ Med* 1999;70(6):583-8. Rec#: 25
   Notes: Considered for efficacy and adverse event analysis.

9. Bell DG, Jacobs I, McLellan TM, Zamecnik J. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect. *Aviat Space Environ Med* 2000;71(4):415-9. Rec#: 26
   Notes: Considered for efficacy and adverse event analysis.

10. Bell DG, Jacobs I, Zamecnik J. Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise. *Eur J Appl Physiol Occup Physiol* 1998;77(5):427-33. Rec#: 27
    Notes: Considered for efficacy and adverse event analysis.

11. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *Int J Obes Relat Metab Disord* 2002;26(5):593-604. Rec#: 474
    Notes: Considered for efficacy and adverse event analysis.

12. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *Int J Obes Relat Metab Disord* 2002;26(5):593-604. Rec#: 34
    Notes: Not considered for analysis. Same trial as Boozer, 2002. Rec#474.

13. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. *Int J Obes Relat Metab Disord* 2001;25(3):316-24. Rec#: 333
    Notes: Considered for efficacy and adverse event analysis.

14. Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. *Int J Obes Relat Metab Disord* 1994;18(2):99-103. Rec#: 41
    Notes: Considered for efficacy and adverse event analysis.

15. Buemann B, Marckmann P, Christensen NJ, Astrup A. The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. *Int J Obes Relat Metab Disord* 1994;18(5):329-32. Rec#: 45
    Notes: Considered for efficacy and adverse event analysis.

16. Colker CM, Kalman DS, Minsch A: Ephedrine, caffeine, and aspirin enhance fat loss under non-exercising conditions. *J Am Coll Nutr* 1997;16:a116(Abstract) Rec#: 546
    Notes: Considered for efficacy and adverse event analysis.

17. Colker CM, Swain MA, Lynch L: A pilot study evaluating the effects of an ephedrine and forskolin-based product on body weight and body composition in overweight, healthy women. *J Am Coll Nutr* 2001;20:a98(Abstract) Rec#: 548
Notes: Considered for efficacy and adverse event analysis.

18. Colker CM, Torina GC, Swain MA, Kalman DS: Double-blind, placebo controlled evaluation of the safety and efficacy of ephedra, caffeine, and salicin for short term weight reduction in overweight subjects. *J Exer Physiol Online* 1999;2:(Abstract) Rec#: 549
Notes: Considered for efficacy and adverse event analysis.

19. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S73-8. Rec#: 68
Notes: Considered for efficacy and adverse event analysis.

20. de Jonge L, Frisard M, Blanchard D, Greenway F. Safety and efficacy of an herbal dietary supplement containing caffeine and ephedra for obesity treatment. *Obesity Research Program Abstracts* 2001;9(Suppl 3):20. Rec#: 316
Notes: Not considered for analysis. Same trial as Greenway, Unpublished. Rec#475.

21. Donikyan LA: *A double-blind randomized, placebo-controlled, multicenter clinical study to evaluate the safety and efficacy of a natural herbal formulation when taken as recommended for weight control. Technical Report Version #1*, 2002:(UnPub) Rec#: 509
Notes: Considered for efficacy and adverse event analysis.

22. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. *Int J Obes* 1986;10(6):467-81. Rec#: 83
Notes: Considered for efficacy and adverse event analysis.

23. Geissler C A . Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S45-8. Rec#: 97
Notes: Considered for efficacy and adverse event analysis.

24. Greenway F, deJonge L, Blanchard D, et al.: *Evaluation of a dietary herbal supplement containing caffeine and ephedrine on metabolic rate, body composition, serum lipids and tolerability*, (UnPub) Rec#: 475
Notes: Considered for efficacy and adverse event analysis.

25. Greenway FL, Raum WJ, DeLany JP. The effect of an herbal dietary supplement containing ephedrine and caffeine on oxygen consumption in humans. *J Altern Complement Med* 2000;6(6):553-5. Rec#: 106
Notes: Considered for efficacy and adverse event analysis.

26. Ingerslev J, Svendsen TL, Mork A. Is an ephedrine caffeine treatment contraindicated in hypertension? *Int J Obesity Related Metabol Disord* 1997;21(8):666-673. Rec#: 132
Notes: Considered for efficacy and adverse event analysis.

27. Jaedig S, Henningsen NC. Increased metabolic rate in obese women after ingestion of potassium, magnesium- and phosphate-enriched orange juice or injection of ephedrine. *Int J Obes* 1991;15(6):429-36. Rec#: 391
Notes: Considered for efficacy and adverse event analysis.

28. Jensen KB, Dano P, Draeby N, Hansen SH, Kanstrup J. [Elsinore tablets and ephedrine as slimming agents]. *Ugeskr Laeger* 1980;142(23):1499-501. Rec#: 536
Notes: Considered for efficacy and adverse event analysis.

29. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. *Aliment Pharmacol Ther* 1991;5(4):413-8. Rec#: 137
Notes: Considered for efficacy and adverse event analysis.

30. Kaats GR, Aldeman JA: Effects of multiple herbal formulation on body composition, blood chemistry, vital signs and self-reported energy levels and appetite control. *Int J Obesity Related Metabol Disord* 1994;18:145(Abstract) Rec#: 139
Notes: Considered for efficacy and adverse event analysis.

31. Kalman D, Incledon T, Gaunaurd I, et al.: An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra/caffeine weight loss product in healthy overweight adults. *International Journal of Obesity* In Press;(In Press) Rec#: 476
Notes: Considered for efficacy and adverse event analysis.

32. Kalman DS, Colker CM, Shi Q, Swain MA. Effects of a weight-loss aid in healthy overweight adults: Double-blind, placebo-controlled clinical trial. *Curr Therapeut Res* 2000;61(4):199-205. Rec#: 140
Notes: Considered for efficacy and adverse event analysis.

33. Kalman DS, Colker CM, Torina GC, Swain MS: Double-blind, placebo evaluation of the safety and efficacy of an ephedrine and synephrine based product for fat reduction in overweight subjects. *Obs Research* 2000;8:120(Abstract) Rec#: 550
Notes: Considered for efficacy and adverse event analysis.

34. Kettle R, Toubro S, Astrup A. Ephedrine/Caffeine enhances abdominal fat loss in females. *Intl J Obesity Related Metabolic Disorders* 1998;22(suppl 3):S264. Rec#: 510
Notes: Considered for efficacy and adverse event analysis.

35. Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. *Trans Assoc Am Physicians* 1990;103:307-12. Rec#: 151
Notes: Not considered for analysis. Same trial as Daly, 1993. Rec#68.

36. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. *Int J Obes Relat Metab Disord* 1995;19(9):678-85. Rec#: 169
Notes: Considered for efficacy and adverse event analysis.

37. Lumholtz IB, Thorsteinsson B, Wamberg T, et al. [Ephedrine in the treatment of obesity. A double-blind cross-over trial of the effect of Elsinore tablets]. *Ugeskr Laeger* 1980;142(23):1487-90. Rec#: 173
Notes: Considered for efficacy and adverse event analysis.

38. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Juhl E, Quaade F. Ephedrine as an anorectic: the story of the 'Elsinore pill'. *Int J Obes* 1981;5(2):183-7. Rec#: 177
Notes: Considered for efficacy and adverse event analysis.

39. Martinet A, Hostettmann K, Schutz Y. Thermogenic effects of commercially available plant preparations aimed at treating human obesity. *Phytomedicine* 1999;6(4):231-8. Rec#: 335
Notes: Considered for efficacy and adverse event analysis.

40. Moheb MA, Geissler CA, Lancer K: Effect of ephedrine, caffeine, and aspirin, in combinations of weight loss in obese women. *Int J Obesity Related Metabol Disord* 1998;22:S264(Abstract) Rec#: 193
Notes: Considered for efficacy and adverse event analysis.

41. Molnar D . Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S49-52. Rec#: 194
Notes: Considered for efficacy and adverse event analysis.

42. Molnar D, Torok K, Erhardt E, Jeges S. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. *Int J Obes Relat Metab Disord* 2000;24(12):1573-8. Rec#: 195
Notes: Considered for efficacy and adverse event analysis.

43. Morgan JB, York DA, Wasilewska A, Portman J. A study of the thermic responses to a meal and to a sympathomimetic drug (ephedrine) in relation to energy balance in man . *Br J Nutr* 1982;47(1):21-32. Rec#: 197
Notes: Considered for efficacy and adverse event analysis.

44. Nasser JA, Wang V, Chen GC, Solomon JL, Heymsfield SB, Boozer CN: Efficacy trial for weight loss of an herbal supplement of Ma huang and guarana. *FASEB J* 1999;13:A874(Abstract) Rec#: 204
Notes: Not considered for analysis. Same trial as Boozer, 2001. Rec#333.

45. Norregaard J, Jorgensen S, Mikkelsen KL, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. *Clin Pharmacol Ther* 1996;60(6):679-86. Rec#: 210
Notes: Considered for efficacy and adverse event analysis.

46. Oksbjerg N, Meyer T, Hvid-Jacobsen K. [Aerobic training increases the effect of ephedrine on energy expenditure]. *Ugeskr Laeger* 1986;148(32):2021-4. Rec#: 214
Notes: Considered for efficacy and adverse event analysis.

47. Pasquali R, Baraldi G, Cesari MP, et al. A controlled trial using ephedrine in the treatment of obesity. *Int J Obes* 1985;9(2):93-8. Rec#: 220
Notes: Considered for efficacy and adverse event analysis.

48. Pasquali R, Casimirri F, Melchionda N, et al . Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. *Clin Sci (Colch)* 1992;82(1):85-92. Rec#: 222
Notes: Considered for efficacy and adverse event analysis.

49. Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine promote weight loss in low-energy-adapted obese women? *Int J Obes* 1987;11(2):163-8. Rec#: 223
Notes: Considered for efficacy and adverse event analysis.

50. Pasternak HJIBD. Effects of ingesting caffeine and ephedrine on muscular endurance. *Can. J. Appl. Physiol.* 1999;24(5):471. Rec#: 511
Notes: Considered for efficacy and adverse event analysis.

51. Quaade F, Astrup A, Breum L, Toubro S, Hein P. [The effect of an ephedrine/caffeine combination as a supplement to a weight-reducing diet. A randomized, placebo-controlled, double-blind trial]. *Ugeskr Laeger* 1992;154(18):1258-63. Rec#: 230
Notes: Not considered for analysis. Same trial as Astrup, 1992. Rec#7.

52. Roed P, Hansen PW, Bidstrup B, Kaern M, Helles A, Petersen KP. [Elsinore banting tablets. A controlled clinical trial in general practice]. *Ugeskr Laeger* 1980;142(23):1491-5. Rec#: 535
Notes: Considered for efficacy and adverse event analysis.

53. Shannon JR, Gottesdiener K, Jordan J, et al. Acute effect of ephedrine on 24-h energy balance. *Clin Sci (Colch)* 1999;96(5):483-91. Rec#: 243
Notes: Considered for efficacy and adverse event analysis.

54. Shugarman AE. Effect of thermogenic dietary supplements on resting metabolic rate in healthy male and female volunteers. University of Utah. Utah. June, 1998. Rec#: 305
Notes: Considered for efficacy and adverse event analysis.

55. Sidney KH, Lefcoe NM. The effects of ephedrine on the physiological and psychological responses to submaximal and maximal exercise in man. *Med Sci Sports* 1977;9(2):95-9. Rec#: 247
Notes: Considered for efficacy and adverse event analysis.

56. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. *BMJ* 1997;314(7073):29-34. Rec#: 261
Notes: Considered for efficacy and adverse event analysis.

57. Toubro S , Astrup A V , Breum L , Quaade F . Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S69-72. Rec#: 263
Notes: Not considered for analysis. Same trial as Astrup, 1992. Rec#7.

58. Van Mil E, Molnar D: Drug treatment in obese adolescents . *Int J Obesity* 2000;24:S184(Abstract) Rec#: 272
Notes: Considered for efficacy and adverse event analysis.

59. Waluga M , Janusz M , Karpel E , Hartleb M , Nowak A . Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. *Clin Physiol* 1998;18(1):69-76. Rec#: 276
Notes: Considered for efficacy and adverse event analysis.

1. Anonymous. Ephedra herba. *Kiso to Rinsho (Clin Rep)* 1978;12:2125-2131. Rec#: 1

2. Anonymous. Ephedrae Herba, Bundesanzeiger No. 11. *Bundesanzeiger* 1991;11 Rec#: 534

3. AbdallahAH, TyeA, LaPidusJB, PatilP. Effects of ephedrine isomers on myocardial catecholamines. *Life Sci* 1967;6(1):39-43. Rec#: 420

4. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. *Br J Clin Pharmacol* 1985;20(1):61-6. Rec#: 378

5. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. *Am J Clin Nutr* 1980;33(5):989-97. Rec#: 371

6. AHPA. Ephedra Survey Results: 1995-1999. Survey Administered & Results Compiled by: Arthur Andersen LLP. prepared for The American Herbal Products Association. 2000. Rec#: 2

7. Ahrendt DM. Ergogenic aids: counseling the athlete. *American Family Physician* 2001;63(5):913-922. Rec#: 303

8. al-KhalilS, AlkofahiA, el-EisawiD, al-ShibibA. Transtorine, a new quinoline alkaloid from Ephedra transitoria. *J Nat Prod* 1998;61(2):262-3. Rec#: 442

9. Altschuler S, Conte A, Sebok M, Marlin RL, Winick C. Three controlled trials of weight loss with phenylpropanolamine. *Int J Obes* 1982;6(6):549-56. Rec#: 399

10. Anastario GD, Haston P. Fetal tachycardia associated with maternal use of pseudoephedrine and OTC oral decongestant. *J Am Board Fam Pract* 5:527-528. Rec#: 3

11. Anon. Herbal preparation: potential toxicity. Candian Adverse Drug Reaction Newsletter. 4, 1994. pages 3. Rec#: 498

12. Anon. Herbs to handle with care. Newsweek. New York. May 6, 1996. pages 62-3. Rec#: 497

13. Anselme F, Collomp K, Mercier B, Ahmaidi S, Prefaut C. Caffeine increases maximal anaerobic power and blood lactate concentration. *Eur J Appl Physiol Occup Physiol* 1992;65(2):188-91. Rec#: 541

14. Assismos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin - and ephedrine-induced stones. *J Endourol* 1999;13(9):665-7. Rec#: 4

15. Astrup A: *Commentary on safety of products containing ephedrine alkaloids/caffeine*, (UnPub) Rec#: 477

16. Astrup A. Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation. *Acta Endocrinol Suppl (Copenh)* 1986;278:1-32. Rec#: 389

17. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. *Endocrine* 2000;13(2):207-12. Rec#: 5

18. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. *Obes Res* 1995;3 Suppl 4:537S-540S. Rec#: 6

19. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. *Exp Clin Endocrinol Diabetes* 1998;106 Suppl 2:29-34. Rec#: 10

20. Astrup A , Lundsgaard C , Madsen J , Christensen N J . Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. *Am J Clin Nutr* 1985;42(1):83-94. Rec#: 11

21. Astrup A, Madsen J, Holst JJ, Christensen NJ . The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. *Metabolism* 1986;35(3):260-5. Rec#: 387

22. Astrup A , Toubro S . Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S41-3. Rec#: 12

23. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr* 1990;51(5):759-67. Rec#: 499

24. Astrup A, Toubro S, Christensen NJ, Quaade F . Pharmacology of thermogenic drugs. *Am J Clin Nutr* 1992;55(1 Suppl):246S-248S. Rec#: 397

25. Astrup AV. Treatment of obesity with thermogenic agents. *Nutrition* 1989;5(1):70. Rec#: 403

26. Aswal B S , Bhakuni D S , Goel A K , Kar K , Mehrotra B N . Screening of Indian plants for biological activity--Part XI. *Indian J Exp Biol* 1984;22(9):487-504. Rec#: 14

27. Atkinson RL. The herbal ephedra and caffeine debate continues. *International Journal of Obesity* 2002;26:589. Rec#: 531

28. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA. Combined drug treatment of obesity. *Obes Res* 1995;3 Suppl 4:497S-500S. Rec#: 15

29. Audicana M, Urrutia I, Echechipia S, Munoz D, Fernandez de Corres L. Sensitization to ephedrine in oral anticatarrhal drugs. *Contact Dermatitis* 1991; 24(3):223. Rec#: 366

30. Aviado DM, Wnuck AL, De Beer EJ. Cardiovascular effects of sympathomimetic bronchodilators: epinephrine, ephedrine, pseudoephedrine, isoproterenol, mehtoxyphenamine and isoprophenamine. *J Pharmacology and Experimental Therapeutics* 1958;122(407-417) Rec#: 405

31. Axelrod J. Studies on sympathomimetic amines: I. The biotransformation and physiological disposition of 1-ephedrine and 1-norephedrine. *J Pharmacol Exper Therapeut* 1953;109(1):62-73. Rec#: 16

32. Backer R , Tautman D , Lowry S , Harvey C M , Poklis A . Fatal ephedrine intoxication. *J Forensic Sci* 1997;42(1):157-9. Rec#: 17

33. Badiei B, Faciane J, Sly RM. Effect of theophylline, ephedrine and their combination upon exercise-induced airway obstruction. *Ann Allergy* 1975;35(1):32-6. Rec#: 18

34. Bailey CJ, Thornburn CC, Flatt PR. Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. *Gen Pharmacol* 1986;17(2):243-6. Rec#: 388

35. Bale J F Jr, Fountain M T , Shaddy R . Phenylpropanolamine-associated CNS complications in children and adolescents. *Am J Dis Child* 1984;138(7):683-5. Rec#: 19

36. BarnesJ, MillsSY, AbbotNC, WilloughbyM, ErnstE. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. *Br J Clin Pharmacol* 1998;45(5):496-500. Rec#: 439

37. Baselt RC: Caffeine, in Baselt RC (ed): *Drugs and Chemicals in Man (2nd)*. Foster City, CA, Chemical Toxicology Institute; 1982b:108-111. Rec#: 20

38. Baselt RC: Disposition of toxic drugs and chmicals in man, in AnonymousDavis, CA, Biomedical Publictions; 1982:108-111. Rec#: 433

39. Baselt RC: Ephedra, in Baselt RC (ed): *Disposition of Toxic Drugs and Chemicals in Man (2nd)*. Foster City, CA, Chemical Toxicology Institute; 1982a: Rec#: 21

40. Battig K. Acute and chronic cardiovascular and behavioural effects of caffeine, aspirin and ephedrine. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S61-4. Rec#: 22

41. Beck RA, Mercado DL, Seguin SM, Andrade WP, Cushner HM. Cardiovascular effects of pseudoephedrine in medically controlled hypertensive patients. *Arch Intern Med* 1992;152(6):1242-5. Rec#: 23

42. Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. *Med Sci Sports Exerc* 2001;33(8):1399-403. Rec#: 481

43. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. *J Clin Epidemiol* 1993;46(11):1331-6. Rec#: 325

44. Betz JM , Gay ML , Mossoba MM , Adams S , Portz BS . Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Ma Huang. *J AOAC Int* 1997;80(2):303-15. Rec#: 28

45. Bierman CW , Pierson WE , Shapiro GG . Exercise-induced asthma. Pharmacological assessment of single drugs and drug combinations. *JAMA* 1975;234(3):295-8. Rec#: 29

46. Blanc PD , Kuschner WG , Katz PP, Smith S, Yelin EH . Use of herbal products, coffee or black tea, and over-the-counter medications as self-treatments among adults with asthma. *J Allergy Clin Immunol* 1997;100(6 Pt 1):789-91. Rec#: 30

47. Blanc S, Leuenberger P, Berger JP, et al. Judgments of trained observers on adverse drug reactions. *Clinical Pharmacology and Therapeutics* 1979;25(5):493-498. Rec#: 461

48. Blaszyk HJ, Edwards WD. Sudden cardiac death in a healthy 28-year-old male truck driver abusing ephedrine. *J Forensic Sci* 1997;42 (1):169-. Rec#: 348

49. Blau J J . Ephedrine nephrolithiasis associated with chronic ephedrine abuse. *J Urol* 1998;160(3 Pt 1):825. Rec#: 31

50. Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. *BMJ* 1996;312(7031):629-32. Rec#: 533

51. Blumenthal M. FDA Holds Expert Advisory Committee Hearing on Ma Huang: Experts Recommend Appropriate Labeling and Warnings--Not Banning the Herb. *HERBALGRAM* 1996;36:21-3, 73. Rec#: 32

52. Blumenthal M, Busse WR: Ephedra, in Blumenthal M, Busse WR (eds): *(Translated by) Klein S, Rister RS. Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines.* Boston, MA, Integrative Medicine Communications; 125-6, 414-6, 475-6. Rec#: 33

53. Bondi M, Grugni G, Velardo A, et al. Adrenomedullary response to caffeine in prepubertal and pubertal obese subjects. *Int J Obes Relat Metab Disord* 1999;23(9):992-6. Rec#: 376

54. Borum M. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. *American Journal of Gastroenterology* 2001;94:2430-4. Rec#: 521

55. Boston LN. Dysuria following ephedrine therapy. *Me dTimes* 1928;56:94-95. Rec#: 35

56. Boston LN. Dysuria following ephedrine therapy. *The Medical Times* 1928;56(Apr):94-95. Rec#: 302

57. Boullata JI, Nace AM. Safety issues with herbal medicine. *Pharmacotherapy* 2000;20(3):257-69. Rec#: 36

58. Bowyer JF , Newport GD , Slikker W Jr, Gough B , Ferguson SA , Tor-Agbidye J . An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate. *Toxicol Sci* 2000;55(1):133-42. Rec#: 37

59. Bracco D, Ferrarra JM, Arnaud MJ, Jequier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women . *Am J Physiol* 1995;269(4 Pt 1):E671-8. Rec#: 375

60. Bradley JG . Nonprescription drugs and hypertension. Which ones affect blood pressure? *Postgrad Med* 1991;89(6):195-7, 201-2. Rec#: 38

61. Bradley JG, Kallail KJ, Dorsch JN, Fox J. The effects of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial. *J Am Board Fam Pract* 1991;4(4): 201-6. Rec#: 39

62. BraterDC, KaojarernS, BenetLZ, et al. Renal excretion of pseudoephedrine. *Clin Pharmacol Ther* 1980;28(5):690-4. Rec#: 443

63. Bray. Use and abuse of appetite-suppressant drugs in the treatment of obesity. *Ann Intern Med* 1993;119(7 Pt 2):707-13. Rec#: 306

64. Bray GA. Drug treatment of obesity. *Baillieres Best Pract Res Clin Endocrinol Metab* 1999;13(1):131-48. Rec#: 40

65. Bray GA. Evaluation of drugs for treating obesity. *Obesity Research* 1995;3(Suppl 4):425S-434S. Rec#: 551

66. BrightTP, SandageBW= Jr, FletcherHP. Selected cardiac and metabolic responses to pseudoephedrine with exercise. *J Clin Pharmacol* 1981;21(11-12 Pt 1):488-92. Rec#: 416

67. BrittonMG, EmpeyDW, JohnGC, McDonnellKA, HughesDT. Histamine challenge and anterior nasal rhinometry: their use in the assessment of pseudoephedrine and triprolidine as nasal decongestants in subjects with hayfever. *Br J Clin Pharmacol* 1978;6(1):51-8. Rec#: 419

68. Brown N J , Ryder D , Branch R A . A pharmacodynamic interaction between caffeine and phenylpropanolamine. *Clin Pharmacol Ther* 1991;50(4):363-71. Rec#: 42

69. Bruneton J: Phenethylamines, in Bruneton J (ed): *Pharmacognosy, Phytochemistry, Medicinal Plants*. Paris, France, Secausuc, NY, Lavoisier Pub; 1996:711-15. Rec#: 43

70. Bruno A , Nolte K B , Chapin J . Stroke associated with ephedrine use. *Neurology* 1993;43(7):1313-6. Rec#: 44

71. Bucci LR. Selected herbals and human exercise performance. *Am J Clin Nutr* 2000;72(2 Suppl):624S-36S. Rec#: 479

72. Bukowiecki L, Jahjah L, Follea N. Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. *Int J Obes* 1982;6(4):343-50. Rec#: 367

73. Burkhart K K . Intravenous propranolol reverses hypertension after sympathomimetic overdose: two case reports. *J Toxicol Clin Toxicol* 1992;30(1):109-14. Rec#: 46

74. Bye C, Dewsbury D, Peck AW. Effects on the human central nervous system of the two isomers of ephedrine and triprolidine and their interaction. *Br J Clin Pharmacol* 1974;1(1):71-78. Rec#: 47

75. Bye C, Hill HM, Hughes DT, Peck AW. A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. *Eur J Clin Pharmacol* 1975;8(1):47-53. Rec#: 415

76. Capwell RR . Ephedrine-induced mania from an herbal diet supplement. *Am J Psychiatry* 1995;152(4):647. Rec#: 48

77. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. *Int J Obes Relat Metab Disord* 1995;19(4):234-9. Rec#: 380

78. Case B, Oszko MA. Use of an algorithm to evaluate published reports of adverse drug reactions. *Am J Hosp Pharm* 1991;48(1):121-2. Rec#: 331

79. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. *Adv Intern Med* 1991;36:399-424. Rec#: 49

80. CDC. Adverse events associated with ephedrine containing products. *MMWR* 1995;45:689-93. Rec#: 434

81. CDC. Adverse events associated with ephedrine-containing products. *JAMA* 1996;276(21):1711-2. Rec#: 436

82. Cetaruk E W , Aaron C K . Hazards of nonprescription medications. *Emerg Med Clin North Am* 1994;12(2):483-510. Rec#: 50

83. Chait L. Factors influencing the reinforcing and subjective effects of ephedrine in humans. *Psychopharmacology* 1994;113:381-7. Rec#: 520

84. Chance MRA. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. *J Pharmacol Exper Therapeut* 1946;87:214-19. Rec#: 51

85. Chappel CI, Rona G, Balazs T, Gaudry R. Comparison of cardiotoxic actions of certain sympathomimetic amines. *Cdn J Biochem Physiol* 1959;37:35-42. Rec#: 52

86. Chen KK. The acute toxicity of ephedrine. *Proc Soc Exper Biol Med* 1925a;22(7):404-405. Rec#: 53

87. Chen KK. A comparative study of ephedrine, pseudoephedrine and beta-phenyl-ethylamine. *Archives of Internal Medicine* 1927;39:404-411. Rec#: 407

88. Chen KK. A comparative study of synthetic and natural ephedrines. *J Pharmacol Exper Therapeutics* 1928;33:237-258. Rec#: 408

89. Chen KK. The effect of ephedrine on experimental shock and hemorrhage. *Proceedings of the Society for Experimental Biology and Medicine* 1925;22(3):203-206. Rec#: 406

90. Chen KK. The effect of repeated administration of ephedrine. *Proc Soc Exper Biol Med* 1925;22(8):568-570. Rec#: 54

91. Chen KK, Kao CH. Ephedrine and pseudoephedrine, their isolation, constitution, isomerism, properties, derivatives and synthesis. *J Am Pharmaceut Assoc* 1926;15(8):625-639. Rec#: 409

92. Chen KK, Meek WJ. A comparative study of ephedrine, tyramine and epinephrine with special reference to the circulation. *J Pharmacol Exper Therapeut* 1926;28:59-76. Rec#: 411

93. Chen KK, Meek WJ. Further studies on the effect of ephedrine on the circulation. *J Am Pharmaceut Assoc* 1926;28:31-57. Rec#: 410

94. Chen KK, Poth EJ. The racial difference of the mydriatic action of ephedrines, cocaine, and euphthalmine. *Proc Soc Exper Biol Med* 1927;25(2):150-151. Rec#: 413

95. Chen KK, Schmidt CF. The action of ephedrine, the active principle of the Chinese drug Ma Hung. *J Pharmacol Exper Therapeut* 1924;24:339-357. Rec#: 414

96. Chen KK, Schmidt CF. Ephedrine and related substances. *Medicine* 1930;9:1-117. Rec#: 55

97. Chen KK, Wu C-K, Henriksen E. Ephedrine homologs and isomers: Relationship between their pharmacological action and their chemical constitution and stereoisomerism. *Proc Soc Exper Biol Med* 1929;26(4):348. Rec#: 56

98. Chen KK, Wu C-K, Henriksen E. Relationship between the pharmacological action and the chemical constitution and configuration of the optical isomers of ephedrine and related compounds. *J Pharmacol Exper Therapeut* 1929;36:363-400. Rec#: 57

99. Chestnut DH, Weiner CP, Wang JP, Herrig JE, Martin JG. The effect of ephedrine upon uterine artery blood flow velocity in the pregnant guinea pig subjected to terbutaline infusion and acute hemorrhage. *Anesthesiology* 1987;66(4):508-12. Rec#: 370

100. ChicharroM, ZapardielA, BermejoE, PerezJA, HernandezL. Direct determination of ephedrine and norephedrine in human urine by capillary zone electrophoresis. *J Chromatogr* 1993;622(1):103-8. Rec#: 444

101. Chua SS, Benrimoj SI. Non-prescription sympathomimetic agents and hypertension. *Med Toxicol Adverse Drug Exp* 1988;3(5):387-417. Rec#: 58

102. Chua SS, Benrimoj SI, Gordon RD, Williams G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. *Br J Clin Pharmacol* 1989;28(3):369-72. Rec#: 59

103. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. *Sports Med* 1997;24(6):366-84. Rec#: 60

104. Clemons JM, Crosby SL. Cardiopulmonary and subjective effects of a 60 mg dose of pseudoephedrine on graded treadmill exercise. *J Sports Med Phys Fitness* 1993;33(4):405-12. Rec#: 61

105. Clovis WL. Mania and cough syrup. *J Clin Psychiatry* 1993;54(5):200. Rec#: 62

106. Coates ML, Rembold CM, Farr BM. Does pseudoephedrine increase blood pressure in patients with controlled hypertension? *J Fam Pract* 1995;40(1):22-6. Rec#: 63

107. Cockings J G , Brown M . Ephedrine abuse causing acute myocardial infarction. *Med J Aust* 1997;167(4):199-200. Rec#: 64

108. Cohen BM. A double-blind crossover study of ephedrine plus theophylline (Tedral) vs. ephedrine (Tedral without theophylline) after single and multiple dosage. New Jersey. Warner-Labert Research Institute. 1973. Report ID 950-0022. Rec#: 460

109. Colditz GA. Economic costs of obesity. *Am J Clin Nutr* 1992;55(2 Suppl):503S-507S. Rec#: 543

110. Colker CM, Swain MA: Acute in vivo pharmacokinetics of natural source ephedra (ma huang) vs. pure synthetic ephedrine: an open label human trial. *Med Sci Sport Exerc* 2002;34:s231(Abstract) Rec#: 547

111. Costello JF, May CS, Paterson JW, Pickup ME. Pharmacokinetics of ephedrine in asthmatics receiving acute and chronic treatment. *Br J Clin Pharmacol* 1975;2(2): 180-181. Rec#: 65

112. Cowley G. Herbal warning. Newsweek. New York. May 6, 1996. pages 60-8. Rec#: 496

113. Cupp MJ. Herbal remedies: adverse effects and drug interactions. *Am Fam Physician* 1999;59(5):1239-45. Rec#: 66

114. Dalton R . Mixed bipolar disorder precipitated by pseudoephedrine hydrochloride. *South Med J* 1990;83(1):64-5. Rec#: 67

115. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* 1993;46(11):1323-30. Rec#: 328

116. Dangoumau J, Evreux JC, Jouglard J. [Mehtod for determination of undesirable effects of drugs]. *Therapie* 1978;33(3):373-81. Rec#: 323

117. Dawson J K , Earnshaw S M , Graham C S . Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. *J Accid Emerg Med* 1995; 12(1):49-51. Rec#: 69

118. Derreza H , Fine M D , Sadaniantz A . Acute myocardial infarction after use of pseudoephedrine for sinus congestion. *J Am Board Fam Pract* 1997;10(6):436-8. Rec#: 70

119. Dewsnap P , Libby G . A case of affective psychosis after routine use of proprietary cold remedy containing phenylpropanolamine. *Hum Exp Toxicol* 1992;11(4):295-6. Rec#: 71

120. Diaz JL. Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico . *Annu Rev Pharmacol Toxicol* 1977;17:647-75. Rec#: 72

121. Diaz MA WTSG. Self medication with pseudo-ephedrine in a chronically depressed patient. *Amer. J. Psychiat* 1979;136(9):1217-8. Rec#: 527

122. Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man. *Eur J Clin Pharmacol* 1978;14(4):253-9. Rec#: 73

123. Dimson SB. The pressor actions of ephedrine and pseudoephedrine in man. *Q J Pharmacy Pharmacol* Rec#: 412

124. Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide . *J Cardiovasc Pharmacol* 1996;28(6):856-61. Rec#: 74

125. Dollery C: Caffeine, in Dollery C (ed): *Therapeutic Drugs*. New York, NY, Churchill Livingstone; 1991:C3-C6 Rec#: 75

126. Dollery C: Ephedrine (Hydrochloride), in Dollery C (ed): *Therapeutic Drugs*. New York, NY, Churchill Livingstone; 1991:E26-E29 Rec#: 76

127. Dollery C: Phenylpropanolamine (hydrochloride), in Dollery C (ed): *Therapeutic Drugs*. New York, NY, Churchill Livingstone; 1991:P91-P93 Rec#: 77

128. Dollery C: Psuedophedrine hydrochloride, in Dollery C (ed): *Therapeutic Drugs*. New York, NY, Churchill Livingstone; 1991:P297-P299 Rec#: 78

129. Dougherty R. Pseudo-speed: look-alikes or peashooters. *NY State Journal of Medicine* 1982;1:74-75. Rec#: 524

130. Doyle H , Kargin M . Herbal stimulant containing ephedrine has also caused psychosis. *BMJ* 1996;313(7059):756. Rec#: 79

131. Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. *Br J Clin Pharmacol* 1978;6(3):221-5. Rec#: 80

132. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: animal studies. *Am J Clin Nutr* 1986;43 (3):388-94. Rec#: 501

133. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S35-40. Rec#: 81

134. Dulloo AG. Herbal simulation of ephedrine and caffeine in treatment of obesity. *International Journal of Obesity* 2002;26:590-2. Rec#: 532

135. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *Am J Clin Nutr* 1999;70(6):1040-5. Rec#: 396

136. Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. *Am J Clin Nutr* 1989;49 (1):44-50. Rec#: 374

137. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. *Am J Clin Nutr* 1987;45(3):564-9. Rec#: 386

138. Dulloo AG, Miller DS . Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. *Am J Clin Nutr* 1987;45(3):564-9. Rec#: 500

139. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese. *Nutrition* 1989;5(1):7-9. Rec#: 82

140. Dulloo AG, Miller DS. Thermogenic drugs for the treatment of obesity: sympathetic stimulants in animal models. *Br J Nutr* 1984;52 (2):179-96. Rec#: 385

141. Dulloo AG, Seydoux J, Girardier L: Dietary and pharmacological effectiveness of thermogenic stimulation in obesity treatment, in Oomura et al. (ed): *Progress in Obesity Research, 1990*. London, John Libbey and Company, Lt.; 1991:135-144. Rec#: 504

142. Dulloo AG, Seydoux J, Girardier L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. *Int J Obes* 1991;15(5):317-26. Rec#: 364

143. Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord* 2000;24(2):252-8. Rec#: 395

144. Dulloo AG, Stock MJ. Ephedrine in the treatment of obesity. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S1-2. Rec#: 404

145. Dunagan N, Greenleaf JE, Cisar CJ . Thermoregulatory effects of caffeine ingestion during submaximal exercise in men. *Aviat Space Environ Med* 1998;69(12):1178-81. Rec#: 542

146. Dvorak R, Starling RD, Calles-Escandon J, Sims EA, Poehlman ET. Drug therapy for obesity in the elderly. *Drugs Aging* 1997;11(5):338-51. Rec#: 84

147. Dyck DJ. Dietary fat intake, supplements, and weight loss. *Can J Appl Physiol* 2000;25(6):495-523. Rec#: 85

148. Edwards IR, Aronson JK . Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356(9237):1255-9. Rec#: 480

149. Edwards M , Russo L , Harwood-Nuss A . Cerebral infarction with a single oral dose of phenylpropanolamine. *Am J Emerg Med* 1987;5(2):163-4. Rec#: 86

150. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. *Med J Aust* 1999;171(11-12):604-8. Rec#: 402

151. Eldor J . Ephedrine in the initial treatment of haemorrhagic shock. *Med Hypotheses* 1991;35(3):250-2. Rec#: 87

152. Ellenhorn MJ, Barceloux DG: Over-the-counter products, in Ellenhorn MJ, Barceloux DG (eds): *Medical Toxicology: Diagnosis and Treatment of Human Poisoning*. New York, NY, Elsevier; 1988:501-559. Rec#: 88

153. Emanueli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. *Agents Actions Suppl* 1980;7:318-22. Rec#: 321

154. Emmanuel N, Jones C, Lydiard R. Use of herbal products and symptoms of bipolar disorder. *American Journal of Psychiatry* 1998;155:1627. Rec#: 519

155. Emmanuel NP, Jones C, Lydiard RB . Use of herbal products and symptoms of bipolar disorder. *Am J Psychiatry* 1998;155(11):1627. Rec#: 486

156. EmpeyDW, FrosolonoMF, HughesDT, PerkinsJG. Comparison of pseudoephedrine and triprolidine, alone and in combination in preventing nasal congestion in subjects with allergic rhinitis using nasal histamine challenge. *Br J Clin Pharmacol* 1984;18(1):86-9. Rec#: 418

157. EmpeyDW, YoungGA, LetleyE, et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. *Br J Clin Pharmacol* 1980;9(4):351-8. Rec#: 417

158. Escobar JI , Karno M . Chronic hallucinosis from nasal drops. *JAMA* 1982;247(13):1859-60. Rec#: 488

159. Fairchild M D , Alles G A . The central locomotor stimulatory acitivity and acute toxicity of the ephedrine and norephedrine isomers in mice. *J Pharmacol Exp Ther* 1967;158(1):135-9. Rec#: 89

160. FDA. Rockville, MD. Food and Drug Administration. 2000. Rec#: 440

161. FDA. Spontaneous adverse events reports. 2001. [web page] www.fda.gov/ohrms/dockets/ac/slides/3558sle/tsld003.htm. Rec#: 441

162. Feller D R , Malspeis L . Biotransformation of D(-)-ephedrine and L(+)-ephedrine in the rabbit, in vivo and in vitro. *Drug Metab Dispos* 1977;5(1):37-46. Rec#: 90

163. Fillmore CM, Bartoli L, Bach R, Park Y. Nutrition and dietary supplements. *Phys Med Rehabil Clin N Am* 1999;10(3):673-703. Rec#: 91

164. Finer N. Present and future pharmacological approaches [obesity]. *British Medical Bulletin* 1997;53(2):409-432. Rec#: 304

165. Fisher CR, Veronneau SJ. Herbal preparations: a primer for the aeromedical physician. *Aviat Space Environ Med* 2000;71(1):45-60. Rec#: 92

166. Floch A, Lagente V, Freslon JL, Blanc M, Advenier C. [Bronchomotor effects of (-) ephedrine, (+/-) ephedrine and (+) pseudoephedrine in guinea pigs]. *Ann Pharm Fr* 1985;43(1):31-8. Rec#: 369

167. Flordal PA, Svensson J. Hemostatic effects of ephedrine. *Thromb Res* 1992;68(3):295-302. Rec#: 93

168. FlurerCL, LinLA, SatzgerRD, WolnikKA. Determination of ephedrine compounds in nutritional supplements by cyclodextrin-modified capillary electrophoresis. *J Chromatogr B Biomed Appl* 1995;669(1):133-9. Rec#: 447

169. Food and Drug Administration. Assessment of Public Health Risks Associated with the Use of Ephedrine Alkaloid-Containing Dietary Supplements. 2000. Report ID FDA Docket No. 00n-1200. Rec#: 94

170. Frick PA, Cohen LG, Rovers JP. Algorithms used in adverse drug event reports: a comparative study. *Ann Pharmacother* 1997;31(2):164-7. Rec#: 330

171. Fugh-Berman A. Clinical trials of Herbs. *Primary Care - Clinics Office Pract* 1997;24(4):889-903. Rec#: 95

172. Fugh-Berman A, Allina A. Ephedra for Weight Loss. *Alternative Therapies in Women's Health* 2000;2:81-84. Rec#: 312

173. Garcia Ortiz JTMBJ. Nonpigmenting gixed exanthema from ephedrine and pseudoephedrine. *Allergy* 1997;52:229-230. Rec#: 522

174. Garriott J C , Simmons L M , Poklis A , Mackell M A . Five cases of fatal overdose from caffeine-containing "look-alike" drugs. *J Anal Toxicol* 1985;9(3):141-3. Rec#: 96

175. Gaultieri J. Cardiomyopathy in a heavy ephedrine abuser. *J Toxicol Clin Toxicol* 1996;34:581-582. Rec#: 446

176. Gilbert-Barness E, Drut RM. Association of sympathomimetic drugs with malformations . *Vet Human Toxicol* 2000;42(3):168-171. Rec#: 98

177. Gilbert EF, Matsuoka R, Bruyere H, Optiz JM: Teratogenic effect of Tedral (theophylline, ephedrine and phenobarbital) on cardiac development in chick embryos. *Circulation* 1981;64:233(Abstract) Rec#: 99

178. Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. *Br J Clin Pharmacol* 2000;50(3):205-13. Rec#: 100

179. Gillies H, Derman WE, Noakes TD, Smith P, Evans A, Gabriels G. Pseudoephedrine is without ergogenic effects during prolonged exercise. *J Appl Physiol* 1996;81(6):2611-7. Rec#: 101

180. Glennon RAYBWCCTHDP. Cytotoxicity assessment of Mahuang (Ephedra) under different conditions of preparation. *Toxicol Sci* 2000;56:424-30. Rec#: 513

181. Glennon RA, Young R. (+)Amphetamine-stimulus generalization to an herbal ephedrine product. *Pharmacol Biochem Behav* 2000;65(4):655-8. Rec#: 363

182. Glick R , Hoying J , Cerullo L , Perlman S . Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. *Neurosurgery* 1987;20 (6):969-74. Rec#: 102

183. Glidden R S , DiBona F J . Urinary retention associated with ephedrine. *J Pediatr* 1977;90(6):1013-4. Rec#: 103

184. Goldberg LI CMDTeal. Comparative heart contractile force effects of equipressor does of several sympathomimetic amines. *J Pharmacol Exp Ther* 1953;108:177. Rec#: 526

185. Goldfrank L R , Hoffman R S . The cardiovascular effects of cocaine. *Ann Emerg Med* 1991;20(2):165-75. Rec#: 104

186. Gordiecheva NV, Shashkov VS, Kaplan EY, et al. Effectiveness of drugs on physical exercises. *Kosm Ciol Aviakosm Med* 1975;9(5):6-. Rec#: 346

187. Goto M MTTMeal. Studies on the biological action of prescriptions of Chinese medicine containing Ephedra. *Jpn. J. Orient. Med.* 1973;24:1-6. Rec#: 528

188. Graham TE, Spriet LL. Performance and metabolic responses to a high caffeine dose during prolonged exercise. *J Appl Physiol* 1991;71(6):2292-8. Rec#: 539

189. Greening GK. The effect of an antihistamine-pseudoephedrine drug on the blood pressure of moderate hypertensives. *Curr Ther Res Clin Exp* 1969 ;11(5):252-5. Rec#: 427

190. Greenway F. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. *Obesity Reviews* 2001;2:199-211. Rec#: 314

191. Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. *Obes Res* 1999;7(4):370-8. Rec#: 105

192. Greenway FL. Clinical studies with phenylpropanolamine: a meta-analysis. *Am J Clin Nutr* 1992;55 (1 Suppl):203S-205S. Rec#: 307

193. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. *Obes Res* 1999;7(6):523-31. Rec#: 398

194. Griffith JD: Structure-activity relationships of several amphetamine drugs in man, in Ellinwood EH Jr., Kilbey MM (eds): *Cocaine and other stimulants*. New York, NY, Plenum Press; 1977:705-15. Rec#: 107

195. Gruber A J , Pope H G Jr. Ephedrine abuse among 36 female weightlifters. *Am J Addict* 1998;7(4):256-61. Rec#: 108

196. Grunberg E, Randall LO, Schnitzer RJ. The chemotherapeutic and pharmacological properties of the l-ephedrine salt of penicillin G (Tersavin). *J Pharmacol Exper Therapeut* 1949;95:336-346. Rec#: 109

197. Gualtieri J, Harris C: Dilated cardiomyopathy in a heavy ephedrine abuser. *J Toxicol (Clin Toxicol)* 1996;34:581-582.(Abstract) Rec#: 110

198. Gurley BJ, Gardner SF, White LM, Wang P: Ephedrine pharmacokinetics after the ingestion of commercially available herbal preparations of ephedra sinica (Ma-huang). *Pharmaceut Res* 1997;14:S519(Abstract) Rec#: 111

199. Gurley BJ, Gardner SF, White LM, Wang P. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). *Therapeut Drug Monit* 1998;20(4):439-445. Rec#: 112

200. Gurley BJ, Wang P, Gardner SF: Ephedrine alkaloid content of five commercially available herbal products containing ephedra sinica (Ma huang). *Pharmaceut Res* 1997;14 :S582-S582(Abstract) Rec#: 113

201. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma huang) as determined by high performance liquid chromatography. *J Pharmaceut Sci* 1998;87 (12):1547-1553. Rec#: 114

202. Gurley DJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. *Am J Healthy Syst Pharm* 2000;57 Rec#: 115

203. Haffner SM, Knapp JA, Stern MP, Hazuda HP, Rosenthal M, Franco LJ. Coffee consumption, diet, and lipids. *Am J Epidemiol* 1985;122(1):1-12. Rec#: 381

204. Hall RC, Beresford TP, Stickney SK, Nasdahl CS, Coleman JH. Psychiatric reactions produced by respiratory drugs. *Psychosomatics* 1985;26(7):605-8, 615-6. Rec#: 489

205. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. *N Engl J Med* 2000;343(25):1833-8. Rec#: 116

206. Han LK, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of oolong tea. *Int J Obes Relat Metab Disord* 1999;23(1):98-105. Rec#: 393

207. HanzlickR. National Association of Medical Examiners Pediatric Toxicology (PedTox) Registry Report 3. Case submission summary and data for acetaminophen, benzene, carboxyhemoglobin, dextromethorphan, ethanol, phenobarbital, and pseudoephedrine. *Am J Forensic Med Pathol* 1995;16(4):270-7. Rec#: 449

208. Haseman J K . Patterns of tumor incidence in two-year cancer bioassay feeding studies in Fischer 344 rats. *Fundam Appl Toxicol* 1983;3(1):1-9. Rec#: 117

209. Haveson B. Herbal Appetite Suppressant and Weight Loss Composition. Patent-UC-5, 798, 101. 1998 Rec#: 338

210. Hellriegel E T , Bjornsson T D , Hauck W W . Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. *Clin Pharmacol Ther* 1996;60(6):601-7. Rec#: 118

211. Henney JE. Food and Drug Administration, Department of Health and Human Services. Statement Before the Committee on Government Reform, U.S. House of Representatives, Washinton, DC . Mar. 25, 1999. [web page] http://www.fda.gov/ola/1999/dietary.html. Rec#: 119

212. Herridge C F , Brook M F . Ephedrine psychosis. *Br Med J* 1968;2(598):160. Rec#: 120

213. Hirabayashi Y , Saitoh K , Fukuda H , Mitsuhata H , Shimizu R . Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. *Anesthesiology* 1996;84(1):221-4. Rec#: 121

214. Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. *JAMA* 1965;194(11):1259. Rec#: 485

215. Hoffman BB, Lefkowitz RJ: Catecholamines, sympathomimetic drugs, and adrenergic receptors antagonists, in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds): *Goodman and Gillman's The Pharmacological Basis of Therapeutics*. New York, NY, Toronto, ON, McGraw Hill; 1996:199-248. Rec#: 122

216. Horn J, Anderson K. Who in America is trying to lose weight? *Ann Intern Med* 1993;119:672-676. Rec#: 467

217. Horton T J , Geissler C A . Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women. *Int J Obes* 1991;15(5):359-66. Rec#: 123

218. Horton T J , Geissler C A . Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. *Int J Obes Relat Metab Disord* 1996;20(2):91-7. Rec#: 124

219. Howard HJ, Lee TP. The effect of instillations of ephedrine solution upon the eye. *Proc Soc Exper Biol Med* 1927;24(7):700-702. Rec#: 421

220. Hu S: *Botanical, Agricultural, Production and Supply Aspects of Ephedra*, 2000:(UnPub) Rec#: 125

221. Hu SY. Ephedra (ma-huang) in the new Chinese materia medica. *Economic Botany* 1969;23:346-351. Rec#: 505

222. Huber GL: *The benefits and risks of dietary supplements in the practice of bariatric medicine and weight management*, 1999:(UnPub) Rec#: 126

223. Huber GL: *Study on Dietary Supplements for Weight Loss*, 2000:(UnPub) Rec#: 127

224. Hughes DT, Empey DW, Land M. Effects of pseudoephedrine in man. *J Clin Hosp Pharm* 1983;8(4):315-21. Rec#: 128

225. Hughes S C , Ward M G , Levinson G , et al. Placental transfer of ephedrine does not affect neonatal outcome. *Anesthesiology* 1985;63(2):217-9. Rec#: 129

226. Hull KM, Maher TJ. Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. *Pharmacol Biochem Behav* 1992;43(4):1047-52. Rec#: 469

227. Hull KM, Maher TJ. L-tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. *J Pharmacol Exp Ther* 1990;255(2):403-9. Rec#: 470

228. Hull KM, Sanderson WD, Maher TJ. Effect of phenylpropanolamine and related compounds on beta- adrenoceptor-induced activation of adenylyl cyclase. *Life Sci* 1993;52(15):1287-94. Rec#: 468

229. Hull KM, Zanzillari R, Maher TJ. Comparison between phenylpropanolamine and structurally related compounds on gastric transit in the rat. *Pharmacol Biochem Behav* 1993;46(2):411-4. Rec#: 471

230. HurlbutJA, CarrJR, SingletonER, et al. Solid-phase extraction cleanup and liquid chromatography with ultraviolet detection of ephedrine alkaloids in herbal products . *J AOAC Int* 1998;81(6):1121-7. Rec#: 448

231. Hutchins GM. Dietary supplements containing ephedra alkaloids. *N Engl J Med* 2001;344(14):1095-6; discussion 1096-7. Rec#: 353

232. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. *JAMA* 1979;242(7):633-8. Rec#: 326

233. Huxtable R J . The myth of beneficent nature: the risks of herbal preparations. *Ann Intern Med* 1992;117(2):165-6. Rec#: 130

234. hwang EJ, Kan EM, Yang KS, Park SB, Kim TH. Effects of ephedrae herba extract on cellular and humoral immune responses. *Korean J Pharmacog* 1990;21(3):256-. Rec#: 350

235. ICH Steering Committee. Guideline for Good Clinical Practice (ICH Harmonised Tripartite Guideline). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Rec#: 131

236. Insel PA: Beta-adrenergic receptors in pathophysiologic states and in clinical medicine, in Perkins JP (ed): *The Beta-Adrenergic Receptors*. Clifton, NJ, Humana Press; 1991:295-343. Rec#: 133

237. Insel PA, Motusky HJ: Physiologic and pharmacologic regulation of adrenergic receptors, in Insel PA (ed): *Adrenergic Receptors in Man*. New York, NY, Dekker; 1987:201-236. Rec#: 134

238. Ishigooka J , Yoshida Y , Murasaki M . Abuse of "BRON": a Japanese OTC cough suppressant solution containing methylephedrine, codeine, caffeine and chlorpheniramine . *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(4):513-21. Rec#: 135

239. Jacobs I, Bell DG. Acute physical performance effects after ingestion of ephedrine or ephedrine combined with caffeine. 2002; Rec#: 530

240. Jacobs K M , Hirsch K A . Psychiatric complications of Ma-huang. *Psychosomatics* 2000;41(1):58-62. Rec#: 136

241. James LFHKEWWGCBRVJ. Sympathomimetic drug use in adolescents pesenting to a pediatric emergency department with chest pain. *Journal of Toxicology-Clinical Toxicology* 1998;36:321-8. Rec#: 517

242. Jawad SS, EcclesR. Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. *Rhinology* 1998;36(2):73-6. Rec#: 451

243. Jequier E. Energy utilization in human obesity. *Ann N Y Acad Sci* 1987;499:73-83. Rec#: 400

244. Jiang M, Takesi T, Hiromichi O. Effect of ephedra sinica on liposyte lipid metabolism. *Zhongguo Zhongyao Zazhi* 1999;24(5):302-4. Rec#: 339

245. Jones JK: Approaches to evaluation causation of suspected drug reations, in Strom BL., Velo G (eds): *Drug Epidemiology and Post-Marketing Surveillance*. New York, NY, Plenum Press; 1992:103-113. Rec#: 138

246. Josefson D. Herbal stimulant causes US deaths. *BMJ* 1996;312(7044):1441. Rec#: 309

247. Jung RT, Shetty PS, James WP, Barrand MA, Callingham BA. Caffeine: its effect on catecholamines and metabolism in lean and obese humans. *Clin Sci (Colch)* 1981;60(5):527-35. Rec#: 372

248. Kaberi-Otarod J, Conetta R, Kundo KK, Farkash A. Ischemic stroke in a user of Thermadrene: A case study in alternative medicine. *Clin Pharmacol Ther* 2002;72:343-6. Rec#: 552

249. Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. *J Ethnopharmacol* 1991;32(1-3):201-8. Rec#: 452

250. Kalmar JM, Cafarelli E. Effects of caffeine on neuromuscular function. *J Appl Physiol* 1999;87(2):801-8. Rec#: 540

251. Kanai T, Nishikawa T, Satoh A, Kajita A. Cardiovascular teratogenicity of ephedrine in rats. *Senten Ijo (Cong Anom)* 1986;26(3):246. Rec#: 141

252. Kandil A, Shukrallah I, Hussein L, Azmy A. Biological and chemical evaulation of ephedrine. *J Drug Res (Egypt)* 1983;14(1/2):119-122. Rec#: 349

253. Kane FJ Jr, Florenzano R. Psychosis accompanying use of bronchodilator compound. *JAMA* 1971;215(13):2116. Rec#: 490

254. Kanfer I , Dowse R , Vuma V . Pharmacokinetics of oral decongestants. *Pharmacotherapy* 1993;13(6 Pt 2):116S-128S; discussion 143S-146S. Rec#: 142

255. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. *Clin Pharmacol Ther* 1977;21(3):247-54. Rec#: 322

256. Karch S B , Green G S , Young S . Myocardial hypertrophy and coronary artery disease in male cocaine users. *J Forensic Sci* 1995;40(4):591-5. Rec#: 143

257. Karch SB: Ma huang and the ephedra alkaloids, in Cupp MJ (ed): *Toxicology and Clinical Pharmacology of Herbal Products*. Totowa, NJ, Humana Press, Inc; 2000:11-30. Rec#: 144

258. Karch SB: Synthetic stimulants <Fenfluramine, mescaline analogs>, in Karch SB (ed): *The Pathology of Drug Abuse.* Boca Raton, FL, CRC Press; 1993:199-218. Rec#: 145

259. Karch SB: Synthetic stimulants <Phenylpropanolamine>, in Karch SB (ed): *The Pathology of Drug Abuse.* Boca Raton, FL, CRC Press; 1993:165, 177-198. Rec#: 146

260. KarchSB. Comments on "ma huang toxicity" letter by Dr. Theoharides. *J Clin Psychopharmacol* 1999;19(2):196-9. Rec#: 454

261. Kasahara Y, HIkino H, Tsurufuji S, Watanabe M, Ohuchi K. Anti-inflammatory actions of ephedrines in acute inflammations. *Planta Med* 1985;51(4):325-331. Rec#: 351

262. Keld DB, Bendsen AK. [Doping--a medical problem in Denmark?]. *Ugeskr Laeger* 1998;160(33):4749-53. Rec#: 147

263. Kernan W N , Viscoli C M , Brass L M , et al . Phenylpropanolamine and the risk of hemorrhagic stroke. *N Engl J Med* 2000;343(25):1826-32. Rec#: 148

264. Kim TH, Yang KS, Hwang EZ, Park SB. Effect of ephedrae herba on the immune response in mice. *Korean J Pharmacog* 1991;22 (3):183-91. Rec#: 340

265. Kimmel SE, Hutchins GM: *Commentary on the article: "Adverse cardiovascular events temporally associated with Mahuang, an herbal source of ephedrine" published in Mayo Clinic Proceedings, January 2002*, (UnPub) Rec#: 478

266. Kitagawa H, Saito H. Differences in the effect of ephedrine isomers on blood pressure in rats. *Jpn J Pharmacol* 1975;25(4):473-5. Rec#: 356

267. Kizer K W . Intracranial hemorrhage associated with overdose of decongestant containing phenylpropanolamine. *Am J Emerg Med* 1984;2(2):180-1. Rec#: 149

268. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. *Am J Health Syst Pharm* 1999;56(2):125-38; quiz 139-41. Rec#: 150

269. Knight DC, Eden JA. Phytoestrogens: a short review. *Maturitas* 1995;22:167-175. Rec#: 311

270. Kolata G. Appetite suppressants aid obese. New York Times. New York, NY. 4, 1992. pages 9(N), P12(L). Rec#: 466

271. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. *JAMA* 1979;242(7):623-32. Rec#: 327

272. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. *JAMA* 1994;272:205-211. Rec#: 465

273. Kuitunen T , Karkkainen S , Ylitalo P . Comparison of the acute physical and mental effects of ephedrine, fenfluramine, phentermine and prolintane. *Methods Find Exp Clin Pharmacol* 1984;6(5):265-70. Rec#: 152

274. Kustrak D, Ramic A. Ephedra species and the alkaloids of this plants. *Farmaceutski Glasnik_(_FARM. GLAS._)* 1994;50(12):321-339. Rec#: 153

275. Laitinen L A , Empey D W , Bye C , Britton M G , McDonnell K , Hughes D T . A comparison of the bronchodilator action of pseudoephedrine and ephedrine in patients with reversible airway obstruction. *Eur J Clin Pharmacol* 1982;23(2):107-9. Rec#: 154

276. Lake C R , Gallant S , Masson E , Miller P . Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. *Am J Med* 1990;89(2):195-208. Rec#: 155

277. Lake C R , Rosenberg D B , Gallant S , Zaloga G , Chernow B . Phenylpropanolamine increases plasma caffeine levels. *Clin Pharmacol Ther* 1990;47(6):675-85. Rec#: 156

278. Lake CR, Tenglin R, Chernow B, Holloway HC. Psychomotor stimulant-induced mania in a genetically predisposed patient: a review of the literature and report of a case. *J Clin Psychopharmacol* 1983;3(2):97-100. Rec#: 157

279. Lake CQR. CNS stimulants and the look-alike drugs. *Psychiatr Clin North Am* 1984;7:689-701. Rec#: 525

280. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. *Clin Pharmacol Ther* 1995;58(6):692-8. Rec#: 324

281. Law MY, Pedersen GH, Hennen WJ, McCausland CW, Sidwell RW: Subacute toxicity study of ma-huang in mice. *Fundam Appl Toxicol* 1996;30:111(Abstract) Rec#: 158

282. Lee EB. Teratogenicity of the extracts of crude drugs. *Saengyak Hakhoe Chi (Korean J Pharmacognosy)* 1982;13:116-121. Rec#: 159

283. Lee M K , Cheng B W , Che C T , Hsieh D P . Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. *Toxicol Sci* 2000;56(2):424-30. Rec#: 160

284. Lee MK, Wong YK, Che CT, Hsieh DPH: Adrenergic agonists effects and cyto-toxicity of Chinese ephedra (ma-huang) used for weight reduction. *Toxicologist* 1999;48:58(Abstract) Rec#: 161

285. LefebvreRA, SurmontF, BouckaertJ, MoermanE. Urinary excretion of ephedrine after nasal application in healthy volunteers. *J Pharm Pharmacol* 1992;44(8):672-5. Rec#: 450

286. Lefkowitz RJ, Hoffman BB, Taylor P: Neurohumoral transmission: The autonomic and somatic motor nervous systems, in Gilman AG, Rall TW, Nies AS, Taylor P (eds): *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. New York, NY, Toronto, ON, Pergamon Press Ltd; 1990:89-90. Rec#: 162

287. Leung AY, Foster S: Ephedra, in Leung AY, Foster S (eds): *Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics*. New York, NY, John Wiley; 1996:227 Rec#: 163

288. Levine B , Jones R , Klette K , Smith M L , Kilbane E . An intoxication involving BRON and verapamil. *J Anal Toxicol* 1993;17 (6):381-3. Rec#: 164

289. Levitsky DA, Strupp BJ. Direct and indirect thermogenic effects of anorectic drugs. *Adv Nutr Res* 1985;7:187-201. Rec#: 165

290. Li Q, Li BH. [Comparison of central stimulating effects between ephedrine and apomorphine]. *Zhongguo Yao Li Xue Bao* 1991;12(5):468-71. Rec#: 365

291. Liljestrand SH. The action of pseudoephedrine. I. On the isolated uterus and bladder. *Chung-Kuo Sheng Li Hsueh Tsa Chih* 1929;3:249-. Rec#: 343

292. Lindahl A , Sandstrom R , Ungell A L , et al . Jejunal permeability and hepatic extraction of fluvastatin in humans. *Clin Pharmacol Ther* 1996;60(5):493-503. Rec#: 166

293. Lindqvist A, Jalonen J, Laitinen LA, Seppala T, Stromberg C. The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. *Clin Auton Res* 1996;6(6):343-9. Rec#: 167

294. Lindsay BD. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994? *Mayo Clin Proc* 2002;77(1):7-9. Rec#: 472

295. LinET, BraterDC, BenetLZ. Gas-liquid chromatographic determination of pseudoephedrine and norpseudoephedrine in human plasma and urine. *J Chromatogr* 1977;140(3):273-9. Rec#: 431

296. Ling M, Piddlesden SJ, Morgan BP. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. *Clin Exp Immunol* 1995;102(3):582-8. Rec#: 334

297. Liu XX. [Pharmacologic action and clinical use of herbal Ephedrae]. *Zhong Xi Yi Jie He Za Zhi* 1989;9(4):255-6. Rec#: 168

298. Liu YM, Sheu SJ, Chiou SH, Chang HC, Chen YP. A comparative study on commercial samples of Ephedra Herba. *Planta Medica* 1993;59:376-378. Rec#: 506

299. Loizou L A , Hamilton J G , Tsementzis S A . Intracranial haemorrhage in association with pseudoephedrine overdose. *J Neurol Neurosurg Psychiatry* 1982;45(5):471-2. Rec#: 170

300. Loosmore S , Armstrong D . Do-Do abuse. *Br J Psychiatry* 1990;157:278-81. Rec#: 171

301. Lowell BB, Napolitano A, Usher P, et al. Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. *Endocrinology* 1990;126(3):1514-20. Rec#: 392

302. LSRO. Alternative and Traditional Models for Safety Evaluation of Food Ingredients. Prepared for: Center for Food Safety and Applied Nutrition Food and Drug Administration Department of Health and Human Services, Washington DC 20204, under FDA Contract No. 223-92-2195, Task Order #9. Bethesda, MD. Life Sciences Research Office, American Society for Nutritional Sciences. 1998. Rec#: 172

303. Lustik S J , Chhibber A K , van Vliet M , Pomerantz R M . Ephedrine-induced coronary artery vasospasm in a patient with prior cocaine use. *Anesth Analg* 1997;84(4):931-3. Rec#: 174

304. LyonCC, TurneyJH. Pseudoephedrine toxicity in renal failure. *Br J Clin Pract* 1996;50(7):396-7. Rec#: 453

305. Machii S. Pharmacological studies on the optical isomers of ephedrine and pseudoephedrine. *Nippon Yakurigaku Zasshi* 1957;53:638-. Rec#: 344

306. Maertens P , Lum G , Williams J P , White J . Intracranial hemorrhage and cerebral angiopathic changes in a suicidal phenylpropanolamine poisoning. *South Med J* 1987;80(12):1584-6. Rec#: 175

307. Mahdihasan S. Ephedra the oldest medicinal plant with the history of an uninterrupted use . *Ancient Sci Life* 1987;7(2):105-9. Rec#: 176

308. MaitaiCK. D-norpseudoephedrine as an anti-asthmatic: comparison with l-ephedrine, d-pseudoephedrine. *East Afr Med J* 1975;52(6):330-2. Rec#: 425

309. Mariani PJ. Pseudoephedrine-induced hypertensive emergency: treatment with labetalol. *Am J Emerg Med* 1986;4(2):141-2. Rec#: 310

310. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. *Clin Pharmacol Ther* 1971;12 (2):245-58. Rec#: 178

311. Martinez FV, Badas AJ, Goitia JFG, Aguirre I . Generalized dermatitis due to oral ephedrine. *Contact Dermatit* 1993;29(4):215-216. Rec#: 179

312. Marvola M . Effect of acetylated derivatives of some sympathomimetic amines on the acute toxicity, locomotor activity and barbiturate anaesthesia time in mice. *Acta Pharmacol Toxicol (Copenh)* 1976;38(5):474-89. Rec#: 180

313. Marvola M , Kivirinta R . Pharmacokinetics and locomotor activity increasing effect of ephedrine in mice. *Acta Pharmacol Toxicol (Copenh)* 1978;43(5):381-6. Rec#: 181

314. Massoudi M, Evans E, Miller DS. Thermogenic drugs for the treatment of obesity: screening using obese rats and mice. *Ann Nutr Metab* 1983;27(1):26-37. Rec#: 384

315. Massoudi M , Miller D S . Ephedrine, a thermogenic and potential slimming drug. *Proc Nutr Soc* 1977;36(3):135A. Rec#: 182

316. Matsuoka R , Gilbert E F , Bruyers H Jr, Optiz J M . An aborted human fetus with truncus arteriosus communis--possible teratogenic effect of Tedral. *Heart Vessels* 1985;1(3):176-8. Rec#: 183

317. Matthews G, Smolinske S, White S: Ephedrine-related stroke in a teenager. *J Toxicol (Clin Toxicol)* 1997;35:555(Abstract) Rec#: 184

318. May C S , Paterson J W , Spiro S G , Johnson A J . Effect of intravenous injection of salbutamol in asthma. *Br J Clin Pharmacol* 1975;2(6):495-501. Rec#: 185

319. McCleave DJ, Phillips PJ, Vedig AE. Compartmental shift of potassium--a result of sympathomimetic overdose. *Aust N Z J Med* 1978;8(2):180-3. Rec#: 482

320. McKenna D. Ma huang. INPR. 2001. Report ID Ephedra 2.1. Rec#: 508

321. McLaurin JQ, Shipman WF, Rosedale R. Oral decongestants. A double blind comparison study of the effectiveness of four sympathomimetic drugs: Objective and subjective . *Laryngoscope* 1961;71:54-67. Rec#: 186

322. McNamara SH. FDA Has Adequate Power and Authority to Protect the Public From Unsafe Dietary Supplements. *HERBALGRAM* 1996;38:25-7. Rec#: 187

323. Mendez M F . Mania self-induced with cough syrup. *J Clin Psychiatry* 1992;53(5):173-4. Rec#: 188

324. Midha K K , Cooper J K , McGilveray I J . Simple and specific electron-capture GLC assay for plasma and urine ephedrine concentrations following single doses. *J Pharm Sci* 1979;68(5):557-60. Rec#: 189

325. Miller D K , McMahon L R , Green T A , Nation J R , Wellman P J . Repeated administration of ephedrine induces behavioral sensitization in rats. *Psychopharmacology (Berl)* 1998;140(1):52-6. Rec#: 190

326. Miller DS. A controlled trial using ephedrine in the treatment of obesity. *Int J Obes* 1986;10(2):159-60. Rec#: 191

327. Miller TG. A consideration of the clinical value of ephedrine. *American Journal of Medical Science* 1925;170:157-181. Rec#: 507

328. Minimatsu S, Kobayashi Y, Kobayashi N, Juhii Y, Aburada M, Yamushita M. Acute ephedra herba and ephedrine poisoning in mice. *Chudoku Kenkyu* 1991;4:143-149. Rec#: 192

329. Mitsuya H. [Toxic psychosis due to ephedrine-containing antasthmatics--report of three cases (author's transl)]. *Seishin Shinkeigaku Zasshi* 1978;80(4):155-68. Rec#: 491

330. Molenaar PC, Biewenga JE, Van Kempen GT, De Priester JA. Effect of ephedrine on muscle weakness in a model of myasthenia gravis in rats. *Neuropharmacology* 1993;32(4):373-6. Rec#: 355

331. Moolenaar M, Desmond PA, Mascord DJ, Starmer GA, Tattam B, Volkerts ER. The effects of ephedrine on the development of fatigue in a prolonged driving related task. *Hum Psychopharmacol Clin Exp* 1999;14(6):415-427. Rec#: 345

332. Mores N, Campia U, Navarra P, Cardillo C, Preziosi P. No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers. *Eur J Clin Pharmacol* 1999;55(4):251-4. Rec#: 196

333. Morgan JP: *Phenylpropanolamine: A Critical Analysis of Reported Adverse Reactions and Overdosage*, Fort Lee, NJ, Jack K. Burgess, Inc.; 1986: Rec#: 198

334. Morgan JP, Funderburk FR. Phenylpropanalomine and blood pressure: a review of prospective studies. *Am J Clin Nutr* 1992;55(1 Suppl):206S-210S. Rec#: 463

335. Morimoto I , Watanabe F , Osawa T , Okitsu T , Kada T . Mutagenicity screening of crude drugs with Bacillus subtilis rec-assay and Salmonella/microsome reversion assay. *Mutat Res* 1982;97(2):81-102. Rec#: 199

336. Morris HG, Rusnak SA, Selner JC, Barzens K, Barnes J. Comparative effects of ephedrine on adrenergic responsiveness in normal and asthmatic subjects. *J Allergy Clin Immunol* 1978;61(5):294-302. Rec#: 200

337. Mortimer E A Jr. Drug toxicity from breast milk? *Pediatrics* 1977;60(5):780-1. Rec#: 201

338. Mueller SM, Solow EB. Seizures associated with a new combination "pick-me-up" pill. *Ann Neurol* 1982;11(3):322. Rec#: 487

339. Nadeau SE. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol* 1984;15(1):114-5. Rec#: 484

340. NadeauSE. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol* 1984;15(1):114-5. Rec#: 455

341. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. *Am J Gastroenterol* 1996;91(7):1436-8. Rec#: 202

342. Nagai N. *Pharm Seit* 1887;32:700. Rec#: 529

343. NakaharaY, KikuraR. Hair analysis for drugs of abuse. XIX. Determination of ephedrine and its homologs in rat hair and human hair. *J Chromatogr B Biomed Sci Appl* 1997;700(1-2):83-91. Rec#: 456

344. Namba T , Kubo M , Kanai Y , Namba K , Nishimura H , Qazilbash N A . Pharmacognostical studies of Ephedra plants Part I - The comparative histological studies on Ephedra rhizomes from Pakistan and Afghanistan and Chinese crude drugs "Ma-Hung-Gen" . *Planta Med* 1976;29(3):216-25. Rec#: 203

345. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981;30(2):239-45. Rec#: 319

346. National Academy of Sciences (NAS). National Academy of Sciences Model: Dietary Reference Intakes: A Risk Assessment Model for Establishing Upper Intake Levels for Nutrients. Washington DC. Institute of Medicine, National Academy Press (NAP). 1998. Rec#: 205

347. Nelson HS, Black JW, Branch LB, et al. Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals. *J Allergy Clin Immunol* 1975;55(5):299-309. Rec#: 206

348. Nesheim MC. What is the research base for the use of dietary supplements? *Public Health Nutr* 1999;2(1):35-8. Rec#: 538

349. Neve K A , Molinoff P B . Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. *Am J Cardiol* 1986;57(12):17F-22F. Rec#: 207

350. Nielsen B, Atrup A , Samuelsen P , Wengholt H , Christensen NJ. Effect of physical training on thermogenic responses to cold and ephedrine . *Int J Obes Relat Metab Disord* 1993;17(7):383-90. Rec#: 308

351. Nightingale SL. From the Food and Drug Administration. *JAMA* 1996;275(20):1534. Rec#: 495

352. Nightingale SL. From the Food and Drug Administration. *JAMA* 1996;276(21):1710. Rec#: 502

353. NIOSH. Registry of Toxic Effects of Chemical Substances, Centers for Disease Control and Prevention. Ephedrine. 1997. Rec#: 208

354. Nishikawa T, Bruyere HJ= Jr, Gilbert EF, Takagi Y. Potentiating effects of caffeine on the cardiovascular teratogenicity of ephedrine in chick embryos. *Toxicol Lett* 1985;29(1):65-8. Rec#: 360

355. Nishikawa THJ, Bruyere Jr HJ, Takagi Y, Gilbert EF, Uno H . Cardiovascular teratogenicity of ephedrine in chick embryos. *Toxicol Lett* 1985;29(1):59-63. Rec#: 209

356. Noble R. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine. *Drug Intell Clin Pharm* 1988;22(4):296-9. Rec#: 382

357. NTP. Toxicology and Carcinogenesis Studies of Ephedrine Sulfate (CAS No. 134-72-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) National Toxicology Program (NTP), Research Triangle Park, NC, (NTP Technical Reports Series) No. 307. 1986. Rec#: 211

358. Nuotto E. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man. *Eur J Clin Pharmacol* 1983;24(5):603-9. Rec#: 212

359. Nyland H. [Ephedrine, abuse and psychosis]. *Tidsskr Nor Laegeforen* 1973;93(27):2027-9. Rec#: 213

360. Oberman Z, Herzberg M, Jaskolka H, Harell A, Hoerer E, Laurian L. Changes in plasma cortisol, glucose and free fatty acids after caffeine ingestion in obese women. *Isr J Med Sci* 1975;11(1):33-6. Rec#: 373

361. Ogden JA. Congenital anomalies of the coronary arteries. *Am J Cardiol* 1970;25(4):474-9. Rec#: 545

362. Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. *South Med J* 1998;91 (12):1153-5. Rec#: 215

363. Ooms TG, Khan SA, Means C. Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999). *J Am Vet Med Assoc* 2001;218(2):225-9. Rec#: 216

364. Oosterbaan R , Burns M J . Myocardial infarction associated with phenylpropanolamine. *J Emerg Med* 2000;18(1):55-9. Rec#: 217

365. Pace S: Ma huang food supplement toxicity in two adolescents. *J Toxicol (Clin Toxicol)* 1996;34:598(Abstract) Rec#: 218

366. Pantelis C, Hindler CG, Taylor JC. Use and abuse of khat (Catha edulis): a review of the distribution, pharmacology, side effects and a description of psychosis attributed to khat chewing. *Psychol Med* 1989;19(3):657-68. Rec#: 219

367. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity. *Int J Obes Relat Metab Disord* 1993;17 Suppl 1:S65-8. Rec#: 221

368. Pasquali R, Cesari MP, Besteghi L, Melchionda N, Balestra V. Thermogenic agents in the treatment of human obesity: preliminary results. *Int J Obes* 1987;11 Suppl 3:23-6. Rec#: 390

369. Patil PN, Tye A, Lapidus JB. A pharmacological study of the ephedrine isomers. *J Pharmacol Exper Therapeut* 1965;148(2):158-168. Rec#: 422

370. Pentel P. Toxicity of over-the-counter stimulants. *JAMA* 1984;252(14):1898-903. Rec#: 368

371. Pere JC, Begaud B, Haramburu F, Albin H. Computerized comparison of six adverse drug reaction assessment procedures. *Clin Pharmacol Ther* 1986;40(4):451-61. Rec#: 329

372. Perrota DM, Coody G, Culmo C. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. *JAMA* 1996;276(21):1711-1712. Rec#: 224

373. Peterson D I , Hardinge M G . The effect of various environmental factors on cocaine and eph edrine toxicity. *J Pharm Pharmacol* 1967;19(12):810-4. Rec#: 225

374. Pi-Sunyer XF. Medical hazards of obesity. *Ann Intern Med* 1993;119(7 pt 2):655-660. Rec#: 464

375. Pickup M E , May C S , Ssendagire R , Paterson J W . The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. *Br J Clin Pharmacol* 1976;3(1):123-34. Rec#: 226

376. Pickupp ME, Paterson JW. The determination of ephedrine plasma levels by a gas chromatographic method. *J Pharm Pharmacol* 1974;26:561-62. Rec#: 432

377. Pomerantz B , O'Rourke R A . The Stokes-Adams syndrome. *Am J Med* 1969;46(6):941-60. Rec#: 227

378. PortaM, JickH, HabakangasJA. Follow-up study of pseudoephedrine users. *Ann Allergy* 1986;57(5):340-2. Rec#: 426

379. Powell T, et al. Dangers of Ma-huang. *Alternative Medicine Alert* 1998;1:119. Rec#: 313

380. Powell T, et al. Ma-huang strikes again: Ephedrine nephrolithiasis. *Am J Kidney Dis* 1998;32:153-159. Rec#: 318

381. Powell T , Hsu F F , Turk J , Hruska K . Ma-huang strikes again: ephedrine nephrolithiasis. *Am J Kidney Dis* 1998;32(1):153-9. Rec#: 228

382. Puar H S . Acute memory loss and nominal aphasia caused by phenylpropanolamine. *South Med J* 1984;77(12):1604-5. Rec#: 229

383. Raadstroem M, Bengtssonk J, Ederberg S, Bengtson A, Loswick AC, Bengtson JP. Effects of ephedrine on oxygen consumption and cardiac output. *Acta Anaesthesiol Scand* 1995;39(8):1084-87. Rec#: 347

384. Radstrom M, Bengtsson J, Ederberg S, Bengtsson A, Loswick AC, Bengtson JP. Effects of ephedrine on oxygen consumption and cardiac output. *Acta Anaesthesiol Scand* 1995;39(8):1084-7. Rec#: 231

385. Ramsey J J , Colman R J , Swick A G , Kemnitz J W . Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. *Am J Clin Nutr* 1998;68(1):42-51. Rec#: 232

386. Rang HP, Dale MM: *Pharmacology*, NewYork, NY, Churchill Livingstone Inc.; 1995: Rec#: 233

387. Read BE, Feng/ CT. The alleged ephedrine action of two california species of ephedra. *Proc Soc Exp Biol Med* 1927;24:819-21. Rec#: 342

388. Renwick A G . The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values. *Regul Toxicol Pharmacol* 1995;22(3):250-61. Rec#: 234

389. Renwick A G , Lazarus N R . Human variability and noncancer risk assessment- An analysis of the default uncertainty factor. *Regul Toxicol Pharmacol* 1998;27(1 Pt 2):3-20. Rec#: 235

390. Robertson D , Frolich J C , Carr R K , et al . Effects of caffeine on plasma renin activity, catecholamines and blood pressure. *N Engl J Med* 1978;298(4):181-6. Rec#: 236

391. Rogers P, Eftimiades M, Aunapu G, Keller M, Jones R. Lethal but legal: an over-the-counter high takes the life of a college student. *People* 1996;45(20):105-109. Rec#: 462

392. Rosene JM, Rosene JA, Koczajowski DL, Paolone VJ. Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during--6 degrees of head down tilt. *Aviat Space Environ Med* 1999;70(1):15-21. Rec#: 237

393. RothRP, CantekinEI, BluestoneCD, WelchRM, ChoYW. Nasal decongestant activity of pseudoephedrine. *Ann Otol Rhinol Laryngol* 1977;86(2 pt. 1):235-42. Rec#: 428

394. Roxanas M G , Spalding J . Ephedrine abuse psychosis. *Med J Aust* 1977;2(19):639-40. Rec#: 238

395. Rutstein HR. Ingestion of pseudoephedrine. *Arch Otolaryngol* 1963;77:145-47. Rec#: 423

396. Ryan DH. Medicating the obese patient. *Endocrinol Metab Clin North Am* 1996;25(4):989-1004. Rec#: 239

397. Sagara K , Oshima T , Misaki T . A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. *Chem Pharm Bull (Tokyo)* 1983;31(7):2359-65. Rec#: 240

398. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. *Mayo Clin Proc* 2002;77(1):12-6. Rec#: 473

399. Saunders A, Elliott P. Pseudoephedrine in the hypertensive patient. *Australian J Hospit Pharm* 1987;17(2):150-151. Rec#: 424

400. Sawynok J. Pharmacological rationale for the clinical use of caffeine. *Drugs* 1995;49(1):37-50. Rec#: 383

401. Schryver T. The buzz about ephedra and caffeine. *Dietitian's Edge* 2001;March Apr:30-31, 33-34. Rec#: 315

402. Schuckit MA. Ma-huang (Ephedrine) abuse and dependence. *Drug Abuse Alcohol Newsl* 1996;25(5):1-4. Rec#: 337

403. Scroggie DA, Harris M, Sakai L. Rhabdomyolysis associated with nutritional supplement use. *Journal of Clinical Rheumatology_(_J. CLIN. RHEUMATOL._)* 2000; Rec#: 241

404. Sever P S , Dring L G , Williams R T . The metabolism of (-)-ephedrine in man. *Eur J Clin Pharmacol* 1975;9(2-3):193-8. Rec#: 242

405. Sharma AN, Cinci PM, Hoffman RS: Ma huang-induced myocardial infarction with normal coronary arteries. *J Toxicol (Clin Toxicol)* 2000;38:521(Abstract) Rec#: 244

406. Shenfield G M . Combination bronchodilator therapy. *Drugs* 1982;24(5):414-39. Rec#: 245

407. Sheu S-J. Identification by chemical analysis of the botanical sources of commercial samples of Chinese herbal drugs. *Yao Wu Shih P'in Fen Hsi (J Food Drug Anal)* 1997;5(4):285-294. Rec#: 246

408. Shu H, Jin B, Yang Z. The mechanism of inhibitory action of ephedrine on the twitch response of mouse vas deferens to field stimulation. *Sheng Li Hsueh Pao* 1986;38(6):583-88. Rec#: 352

409. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. *Brain Res* 1993;623(1):167-71. Rec#: 358

410. Sinsheimer J E , Dring L G , Williams R T . Species differences in the metabolism of norephedrine in man, rabbit and rat. *Biochem J* 1973;136(3):763-71. Rec#: 248

411. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents. *Ann Pharmacother* 1992;26(5):653-9. Rec#: 249

412. Snook C, Otten M, Hassan M: Massive ephedrine overdose: Case report and toxicokinetic analysis. *Vet Hum Toxicol* 1992;34:335(Abstract) Rec#: 250

413. Sobal J, Marquart LF. Vitamin/mineral supplement use among athletes: a review of the literature. *Int J Sport Nutr* 1994;4(4):320-34. Rec#: 537

414. Sprague JE, Harrod AD, Teconchuk AL. Pharmacology and abuse potential of ephedrine. *Pharm Times* 1998;64:72-80. Rec#: 251

415. Stoessl A, Young G, Feasby T. Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. *Stroke* 1985;16:734-6. Rec#: 514

416. Stromberg C , Vanakoski J , Olkkola K T , Lindqvist A , Seppala T , Laitinen L A . Exercise alters the pharmacokinetics of midazolam. *Clin Pharmacol Ther* 1992;51(5):527-32. Rec#: 252

417. Swain RA, Harsha DM, Baenziger J, Saywell RM . Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? *Clin J Sport Med* 1997;7(3):168-73. Rec#: 253

418. Tagliabue A, Terracina D, Cena H, Turconi G, Lanzola E, Montomoli C. Coffee induced thermogenesis and skin temperature. *Int J Obes Relat Metab Disord* 1994;18(8):537-41. Rec#: 377

419. Takaku T, Ming J, Okuda H, Maeda N. Isolation of inuslin-like substances from ephedra sinica stapf. *Wakan Iyakugaku Zasshi* 1997;14(4):358-9. Rec#: 332

420. TakayasuT, OhshimaT, OhtsujiM, et al. False identification of urinary ephedrine as methamphetamine by gas chromatography/mass spectrometry with a DB-17 column. *Nippon Hoigaku Zasshi* 1997;51(3):235-40. Rec#: 459

421. Tamada M, Endo K, Hikino H. Maokonine, hypertensive principle of Ephedra roots. *Planta Med* 1978;34(3):291-3. Rec#: 336

422. Tamada M, Endo K, Hikino H, Kabuto C. Structure of Ephedradine A, a hypotensive principle of ephedra roots. *Planta Med* 1978;34 :291. Rec#: 341

423. Tanaka M, Dohi S. [The effects of ephedrine and phenylephrine on arterial partial pressure of oxygen during one-lung ventilation]. *Masui* 1994;43(8):1124-9. Rec#: 254

424. Tang DH. Ephedra ('Ma huang'). *Clin Toxicol Rev* 1996;18(10) Rec#: 255

425. Tashkin DP, Meth R, Simmons DH, Lee YE. Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine. *Chest* 1975;68(2):155-61. Rec#: 256

426. Taylor DM, O'Toole KS, Auble TE, Ryan CM, Sherman DR. The psychometric and cardiac effects of pseudoephedrine in the hyperbaric environment. *Pharmacotherapy* 2000 ;20(9):1045-50. Rec#: 257

427. TekolY, TercanE, EsmaogluA. Ephedrine enhances analgesic effect of morphine. *Acta Anaesthesiol Scand* 1994;38(4):396-7. Rec#: 457

428. Theoharides T C . Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. *J Clin Psychopharmacol* 1997;17(5):437-9. Rec#: 258

429. Tinsley JA, Watkins DD. Over-the-counter stimulants: abuse and addiction. *Mayo Clin Proc* 1998;73(10):977-82. Rec#: 493

430. Tinsley JA. The hazards of psychotropic herbs. *Minn Med* 1999;82(5):29-31. Rec#: 259

431. To L B , Sangster J F , Rampling D , Cammens I . Ephedrine-induced cardiomyopathy. *Med J Aust* 1980;2(1):35-6. Rec#: 260

432. Toubro S, Astrup A, Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. *Int J Obes Relat Metab Disord* 1993;17 Suppl 3:S73-7; discussion S82. Rec#: 262

433. Traub S, Hoyek W, Hoffman R. Dietary supplements containing ephedra alkaloids. *New England Journal of Medicine* 2001;344:1096. Rec#: 516

434. Turner J E , Cravey R H . A fatal ingestion of caffeine. *Clin Toxicol* 1977;10(3):341-4. Rec#: 264

435. Tyler VE: Tyler VE (ed): *The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies*. New York, NY, Pharmaceutical Products Press (PPP); 1993:119-121. Rec#: 265

436. Ueng T H , Kang J J , Wang H W , Cheng Y W , Chiang L Y . Suppression of microsomal cytochrome P450-dependent monooxygenases and mitochondrial oxidative phosphorylation by fullerenol, a polyhydroxylated fullerene C60. *Toxicol Lett* 1997;93(1):29-37. Rec#: 266

437. Ueng T-H, Kang J-J, Wang H-W, Lin P-C. An overview of the toxicology of commonly used traditional Chinese medicine. *Yao Wu Shih P'in Fen Hsi (J Food Drug Anal)* 1997;5(4):241-264. Rec#: 267

438. UngerDL. Blood pressure and pulse rate changes in hypertensive asthmatic patients: effects of an ephedrine compound. *Ann Allergy* 1968;26(12):637-8. Rec#: 429

439. United States General Accounting Office. Dietary Supplements: Uncertainties in Analyses Underlying FDA's Proposed Rule on Ephedrine Alkaloids. Washington, DC. United States General Accounting Office. 1999. Rec#: 268

440. Upton R A . Pharmacokinetic interactions between theophylline and other medication (Part I). *Clin Pharmacokinet* 1991;20(1):66-80. Rec#: 269

441. USDA. Dietary supplements containing ephedrine alkaloids; proposed rule. 21 CFR 111. *Federal Register* 1997;62(107):30677-724. Rec#: 445

442. Vahedi K , Domigo V , Amarenco P , Bousser M G . Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. *J Neurol Neurosurg Psychiatry* 2000;68(1):112-3. Rec#: 270

443. Van Mieghem W , Stevens E , Cosemans J . Ephedrine-induced cardiopathy. *Br Med J* 1978;1(6116):816. Rec#: 271

444. Vanakoski J, Seppala T. Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. *Clin Pharmacokinet* 1998;34(4):311-22. Rec#: 273

445. Vanakoski J, Stromberg C, Seppala T. Effects of a sauna on the pharmacokinetics and pharmacodynamics of midazolam and ephedrine in healthy young women. *Eur J Clin Pharmacol* 1993;45(4):377-81. Rec#: 274

446. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. *Biochem Pharmacol* 1999;58(5):807-10. Rec#: 361

447. Venulet J, Ciucci AG, Berneker GC. Updating of a method for causality assessment of adverse drug reactions. *Int J Clin Pharmacol Ther Toxicol* 1986; 24(10):559-68. Rec#: 320

448. Villas Martinez F, Badas AJ, Garmendia Goitia JF, Aguirre I. Generalized dermatitis due to oral ephedrine. *Contact Dermatitis* 1993;29(4):215-6. Rec#: 503

449. Wahl M, Grant C, Jesperson R: Acute psychosis from a dietary weight control supplement. *J Toxicol (Clin Toxicol)* 2000;38:522-523. (Abstract) Rec#: 275

450. Walker RB, Fitz LD, Williams LM, Linton H= Jr, Smith CC. The effect of ephedrine isomers and their oxazolidines on locomotor activity in rats. *Gen Pharmacol* 1993;24(3):669-73. Rec#: 359

451. Warot D, Berlin I, Aymard G, et al: Comparative pharmacodynamics and pharmacokinetics of oral and intranasal ephedrine. *Fun & Clin Pharma* 2000;Abstract 237-297.(Abstract) Rec#: 277

452. Warren MR, Werner HW. Acute toxicity of vasopressor amines: II. Comparative data. *J Pharmacol Exper Therapeut* 1945;86:284-286. Rec#: 278

453. Warren MR, Werner HW. The central stimulant action of some vasopressor amines. *J Pharmacol Exper Therapeut* 1945;85:119-121. Rec#: 279

454. Warren MR, Werner HW: Effect of temperature on the toxicity of some vasopressor amines. *Fed Proc (FASEB)* 1945;4:139(Abstract) Rec#: 280

455. WebbAA, ShiptonEA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. *Can J Anaesth* 1998;45(4):367-9. Rec#: 458

456. Weesner K M , Denison M , Roberts R J . Cardiac arrhythmias in an adolescent following ingestion of an over-the- counter stimulant. *Clin Pediatr (Phila)* 1982;21(11):700-1. Rec#: 281

457. Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ. Interaction of ephedrine and theophylline. *Clin Pharmacol Ther* 1975;17(5):585-92. Rec#: 282

458. Weiner I, TilkianAG, PalazzoloM. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. *Cathet Cardiovasc Diagn* 1990;20(1):51-3. Rec#: 437

459. Welling P G , Lee K P , Patel J A , Walker J E , Wagner J G . Urinary excretion of ephedrine in man without pH control following oral administration of three commercial ephedrine sulfate preparations. *J Pharm Sci* 1971;60(11):1629-34. Rec#: 283

460. Wellman PJ, Miller DK, Livermore CL, Green TA, McMahon LR, Nation JR. Effects of (-)-ephedrine on locomotion, feeding, and nucleus accumbens dopamine in rats. *Psychopharmacology (Berl)* 1998;135(2):133-40. Rec#: 354

461. White L M , Gardner S F , Gurley B J , Marx M A , Wang P L , Estes M . Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults . *J Clin Pharmacol* 1997;37(2):116-22. Rec#: 284

462. Whitehouse A M , Duncan J M . Ephedrine psychosis rediscovered. *Br J Psychiatry* 1987;150:258-61. Rec#: 285

463. WHO. Principles for the Safety Assessment of Food Additives and Contaminants in Food. World Health Organization (WHO), International Programme on Chemical Safety (IPCS), Geneva, Switz. Environmental Health Criteria No. 70. 1987. Rec#: 286

464. Wiener ITAPM. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. *Catheterization & Cardiovascular Diagnosis* 1990;20:51-3. Rec#: 518

465. Wilkinson G R , Beckett A H . Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. *J Pharmacol Exp Ther* 1968;162(1):139-47. Rec#: 287

466. Wilkinson G R , Beckett A H . Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. *J Pharm Sci* 1968;57(11):1933-8. Rec#: 288

467. Williams R, Caldwell J, Dring L: Comparative metabolism of some amphetamines in various species, in Usdin E, Snyder S (eds): *Frontiers in Catecholamine Research*. New York, NY, Pergamon Press; 1973:927-932. Rec#: 289

468. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never- smoking overweight US white women aged 40-64 years. *Am J Epidemiol* 1995;141(12):1128-41. Rec#: 544

469. Wilson A F , Novey H S , Cloninger P , Davis J , White D . Cardiopulmonary effects of long-term bronchodilator administration. *J Allergy Clin Immunol* 1976;58(1 PT. 2):204-12. Rec#: 290

470. Wolf HH, Schuster MA, Lanciault G. 'Aggregation' phenomenon and some ephedrine isomers. *J Pharmaceut Sci* 1964;53:987-988. Rec#: 291

471. Wood KA. Nasal decongestant and psychiatric disturbance. *Br J Psychiatry* 1994;164(4):566-7. Rec#: 492

472. Wooten MR, Khangure MS, Murphy MJ. Intracerebral hemorrhage and vasculitis related to ephedrine abuse. *Ann Neurol* 1983;13(3):337-40. Rec#: 438

473. Xue-Jun Y, De-xiang L, Hechuan W, Yu Z. A study on the mutagenicity of 102 raw pharmaceuticals used in Chinese traditional medicine. *Mutat Res* 1991; 260(1):73-82. Rec#: 292

474. YacobiA, StollRG, ChaoGC, et al. Evaluation of sustained-action chlorpheniramine-pseudoephedrine dosage form in humans. *J Pharm Sci* 1980;69(9):1077-81. Rec#: 430

475. Yale Hemorrhagic Stroke Project Final Study Report. The safety of phenylpropanolamine hydrochloride (PPA) used in OTC weight control and nasal decongestant drug products. 2000. Rec#: 293

476. Yates K M , O'Connor A , Horsley C A . "Herbal Ecstasy": a case series of adverse reactions. *N Z Med J* 2000;113(1114):315-7. Rec#: 294

477. Yen T T , McKee M M , Bemis K G . Ephedrine reduces weight of viable yellow obese mice (Avy/a). *Life Sci* 1981;28(2):119-28. Rec#: 295

478. Yin P. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. *Stroke* 1990;21:1641. Rec#: 515

479. Yin PA. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. *Stroke* 1990;21(11):1641. Rec#: 483

480. Yoovathaworn K C , Sriwatanakul K , Thithapandha A . Influence of caffeine on aspirin pharmacokinetics. *Eur J Drug Metab Pharmacokinet* 1986;11(1):71-6. Rec#: 296

481. Yoshida T, Sakane N, Umekawa T, Kondo M. Relationship between basal metabolic rate, thermogenic response to caffeine, and body weight loss following combined low calorie and exercise treatment in obese women. *Int J Obes Relat Metab Disord* 1994;18(5):345-50. Rec#: 379

482. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M. Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. *Int J Obes Relat Metab Disord* 1995;19(10):717-22. Rec#: 394

483. Young R, Gabryszuk M, Glennon RA. (-)Ephedrine and caffeine mutually potentiate one another's amphetamine- like stimulus effects. *Pharmacol Biochem Behav* 1998;61(2):169-73. Rec#: 357

484. Young R, Glennon RA. Discriminative stimulus properties of (-)ephedrine. *Pharmacol Biochem Behav* 1998;60(3):771-5. Rec#: 494

485. Yuan D, Komatsu K, Cui Z, Kano Y. Pharmacological properties of traditional medicines. XXV. Effects of ephedrine, amygdalin, glycyrrhizin, gypsum and their combinations on body temperature and body fluid. *Biol Pharm Bull* 1999; 22(2):165-71. Rec#: 362

486. Zaacks S M , Klein L , Tan C D , Rodriguez E R , Leikin J B . Hypersensitivity myocarditis associated with ephedra use. *J Toxicol Clin Toxicol* 1999; 37(4):485-9. Rec#: 297

487. Zahn K A , Li R L , Purssell R A . Cardiovascular toxicity after ingestion of "herbal ecstacy". *J Emerg Med* 1999;17(2):289-91. Rec#: 298

488. Zeisel SH. Is there a metabolic basis for dietary supplementation? *Am J Clin Nutr* 2000;72(2 Suppl):507S-11S. Rec#: 299

489. Zgourides GD, Warren R, Englert ME. Ephedrine-induced thermogenesis as an adjunct to cognitive restructuring and covert conditioning: a proposal for treatment of obese individuals. *Percept Mot Skills* 1989;69(2):563-72. Rec#: 401

490. Zhang J, Tian Z, Lou ZC. Simultaneous determination of six alkaloids in Ephedrae herba by high performance liquid chromatography. *Planta Med* 1988;54(1):69-71. Rec#: 300

491. Zhang JS, Tian Z, Lou ZC. Quality evaluation of twelve species of Chinese Ephedra (ma-huang). *Chung Kuo Yao Li Hsueh Pao (Acta Pharmacologica Sinica)* 1993;22:419-425. Rec#: 301